Share this video  

ASH 2022 | Genomic factors influencing patient response to venetoclax-based regimens: analysis from CLL13/GAIA

In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some findings from the Phase III CLL13/GAIA trial (NCT02950051), which is evaluating the safety and efficacy of various venetoclax-based regimens for the treatment of patients with chronic lymphocytic leukemia (CLL). Dr Eichhorst explains the impact of several genomic aberrations on patient response to treatment, and further highlights the need to explore novel treatment approaches for patients with complex karyotype. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter